Arcutis Biotherapeutics (ARQT) Showcased Fresh ZORYVE Data, Is It Still 28% Below Fair Value?

What the new ZORYVE data means for Arcutis Biotherapeutics stock Arcutis Biotherapeutics (ARQT) just used two major dermatology conferences to showcase fresh clinical and real world data across its ZORYVE portfolio, putting the product suite, not macro headlines, at the center of the stock story. Investors now have more detail on how ZORYVE cream and foam are being studied across atopic dermatitis, plaque psoriasis and seborrheic dermatitis, as well as new research on long term topical...